Clinical Trial

Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases

Name: Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases — clinical trial record (NCT06440746)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate efficacy and safety of olokizumab (OKZ) compared to placebo in patients progressive fibrosing Interstitial lung diseases (ILD).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-05-28.

Trial Details

NCT Number	NCT06440746
Lead Sponsor	R-Pharm International, LLC Collaborators: R-Pharm, Exacte Labs LLC, Data Management 365, Keystat, LLC
Conditions	Lung Diseases, Interstitial
Enrollment	138 participants
Start Date	2023-08-23
Primary Completion	2027-04-09 (estimated)
Study Completion	2028-12-25 (estimated)
Updated on ClinicalTrials.gov	2024-11-19